CRISPR’s use has vast potential in basic research to add to the understanding of cellular activity and in healthcare for precision therapies for today’s untreatable diseases. To date, some 30 clinical ...
Editas Medicine said today its lead candidate EDIT-101, an in vivo CRISPR gene editing treatment for Leber congenital amaurosis-10 (LCA10), showed positive initial clinical data showing it to be safe, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback